TPST-1120 is an investigational oral small-molecule selective PPAR-alpha antagonist being developed for advanced solid tumors, including hepatocellular carcinoma combinations with atezolizumab and bevacizumab. Company filings describe dual anti-tumor and immune-modulating effects and ongoing early-phase clinical development. It has no marketing approval.
Tempest Therapeutics reported 2025 financial results showing $7.7 million in cash and highlighted clinical progress including 100% complete response rate in TPST-2003 CAR-T trial and multiple FDA designations for amezalpat in hepatocellular carcinoma. The company completed strategic CAR-T asset acquisition and plans Phase 2b registrational study for its lead program in 2026.
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06680258 |
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy |
NOT_YET_RECRUITING | PHASE3 |
| NCT04524871 |
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) |
RECRUITING | PHASE1/PHASE2 |
